Cargando…

Cannabis-based product use in a multiple sclerosis cohort

OBJECTIVE: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS) patients who attend the University of British Columbia Hospital (UBCH) MS clinic. METHODS: All patients attending the UBCH MS clinic from January to March 2018 were invited...

Descripción completa

Detalles Bibliográficos
Autores principales: Schabas, AJ, Vukojevic, V, Taylor, C, Thu, Z, Badyal, A, Chan, JK, Devonshire, V, Traboulsee, A, Sayao, AL, Carruthers, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764052/
https://www.ncbi.nlm.nih.gov/pubmed/31598330
http://dx.doi.org/10.1177/2055217319869360
_version_ 1783454296005672960
author Schabas, AJ
Vukojevic, V
Taylor, C
Thu, Z
Badyal, A
Chan, JK
Devonshire, V
Traboulsee, A
Sayao, AL
Carruthers, R
author_facet Schabas, AJ
Vukojevic, V
Taylor, C
Thu, Z
Badyal, A
Chan, JK
Devonshire, V
Traboulsee, A
Sayao, AL
Carruthers, R
author_sort Schabas, AJ
collection PubMed
description OBJECTIVE: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS) patients who attend the University of British Columbia Hospital (UBCH) MS clinic. METHODS: All patients attending the UBCH MS clinic from January to March 2018 were invited to participate in an anonymous survey that included: patient demographics (sex, age and employment status), self-reported MS-specific data (subtype, disease duration, previous and current disease modifying therapies, symptomatic medications) and CBP use (formulation, frequency, perceived benefits/side-effects). A second cohort of retrospective patient data (CBP use, sex, age, disease subtype and Expanded Disability Status Scale) was extracted from the UBCH MS clinic electronic medical record (EMR). RESULTS: Of 600 surveys distributed, 188 were returned with completed CBP usage. CBP use was daily for 19% (n = 37), weekly for 6% (n = 11), monthly for 4% (n = 7), rarely for 21% (n = 39) and 50% (n = 94) never used. Of the CBP users (daily, weekly and monthly), CBP use included: oral (n = 43/55), smoked/vaporized (n = 42/55), topical (n = 14/55) and mucosal (n = 5/55). EMR data was available for 561 MS patients where cannabis use/non-use was documented. CBP users represented 19% (107/561). CONCLUSIONS: CBP use is common based on volunteer reporting, with approximately one out of four patients who attend the UBCH MS clinic using CBPs.
format Online
Article
Text
id pubmed-6764052
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67640522019-10-09 Cannabis-based product use in a multiple sclerosis cohort Schabas, AJ Vukojevic, V Taylor, C Thu, Z Badyal, A Chan, JK Devonshire, V Traboulsee, A Sayao, AL Carruthers, R Mult Scler J Exp Transl Clin Original Research Paper OBJECTIVE: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS) patients who attend the University of British Columbia Hospital (UBCH) MS clinic. METHODS: All patients attending the UBCH MS clinic from January to March 2018 were invited to participate in an anonymous survey that included: patient demographics (sex, age and employment status), self-reported MS-specific data (subtype, disease duration, previous and current disease modifying therapies, symptomatic medications) and CBP use (formulation, frequency, perceived benefits/side-effects). A second cohort of retrospective patient data (CBP use, sex, age, disease subtype and Expanded Disability Status Scale) was extracted from the UBCH MS clinic electronic medical record (EMR). RESULTS: Of 600 surveys distributed, 188 were returned with completed CBP usage. CBP use was daily for 19% (n = 37), weekly for 6% (n = 11), monthly for 4% (n = 7), rarely for 21% (n = 39) and 50% (n = 94) never used. Of the CBP users (daily, weekly and monthly), CBP use included: oral (n = 43/55), smoked/vaporized (n = 42/55), topical (n = 14/55) and mucosal (n = 5/55). EMR data was available for 561 MS patients where cannabis use/non-use was documented. CBP users represented 19% (107/561). CONCLUSIONS: CBP use is common based on volunteer reporting, with approximately one out of four patients who attend the UBCH MS clinic using CBPs. SAGE Publications 2019-09-25 /pmc/articles/PMC6764052/ /pubmed/31598330 http://dx.doi.org/10.1177/2055217319869360 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Schabas, AJ
Vukojevic, V
Taylor, C
Thu, Z
Badyal, A
Chan, JK
Devonshire, V
Traboulsee, A
Sayao, AL
Carruthers, R
Cannabis-based product use in a multiple sclerosis cohort
title Cannabis-based product use in a multiple sclerosis cohort
title_full Cannabis-based product use in a multiple sclerosis cohort
title_fullStr Cannabis-based product use in a multiple sclerosis cohort
title_full_unstemmed Cannabis-based product use in a multiple sclerosis cohort
title_short Cannabis-based product use in a multiple sclerosis cohort
title_sort cannabis-based product use in a multiple sclerosis cohort
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764052/
https://www.ncbi.nlm.nih.gov/pubmed/31598330
http://dx.doi.org/10.1177/2055217319869360
work_keys_str_mv AT schabasaj cannabisbasedproductuseinamultiplesclerosiscohort
AT vukojevicv cannabisbasedproductuseinamultiplesclerosiscohort
AT taylorc cannabisbasedproductuseinamultiplesclerosiscohort
AT thuz cannabisbasedproductuseinamultiplesclerosiscohort
AT badyala cannabisbasedproductuseinamultiplesclerosiscohort
AT chanjk cannabisbasedproductuseinamultiplesclerosiscohort
AT devonshirev cannabisbasedproductuseinamultiplesclerosiscohort
AT traboulseea cannabisbasedproductuseinamultiplesclerosiscohort
AT sayaoal cannabisbasedproductuseinamultiplesclerosiscohort
AT carruthersr cannabisbasedproductuseinamultiplesclerosiscohort